- Busenbark Provides Additional Global Corporate Finance, Management and
Manufacturing Experience -
SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of Gordon H. Busenbark to the company's board of directors. Mr. Busenbark currently serves as the chief financial officer of Xytis Pharmaceuticals, a privately held development-stage specialty pharmaceuticals company focused on diseases of the central nervous system.
"With his extensive experience in the pharmaceutical, biotech and vaccine industries, Gordon is a valuable addition to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His 28 years of industry experience include overseeing billion dollar businesses in both the U.S. and Europe. We believe this key global experience, coupled with his proven track record in corporate finance and manufacturing, will serve Nventa well as we continue to advance our lead product candidate through development and toward commercialization."
Prior to joining Xytis in 2007, Mr. Busenbark was the chief financial
officer of Encysive Pharmaceuticals, a publicly traded specialty
pharmaceuticals company focused on vascular disease. In this role, he was
responsible for securing external financing, all aspects of Security and
Exchange Commission (SEC) reporting, Sarbanes-Oxley compliance, budgeting,
forecasting, strategic planning and investor relations activities. From
1981 through 2004, Mr. Busenbark held various leadership positions with
Baxter Healthcare Corporation, including president of Baxter BioScience's
plasma therapeutics business in Vienna, Austria. Mr. Busenbark began his
career as a senior financial analyst at Burroughs Corporation. He received
|SOURCE Nventa Biopharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved